Latest research on Humalog

Insulin lispro is a recombinant human insulin analogue produced in a specialized laboratory strain of Escherischia coli. Plasmid DNA transfected into the bacteria encodes for an analogue of human insulin that has a lysine at residuce B28 and proline at B29; these residues are reversed in endogenous human insulin. Reversal of these amino acid residues produces a rapid-acting insulin analogue. FDA approved on 1996.

Latest findings

Insulin Humalog (Eli Lilly), a human insulin analogue with a structural part exchanged to Lys-Pro (instead of Pro-Lys in insulin) favouring a monomeric nature under physiological conditions [19], was also tested. [source, 2006]
Traditionally, long-acting (e.g. ultralente) insulin is discontinued 2–3 days before surgery, and the patient is stabilized on a regimen of intermediate-acting (neutral protamine hagedorn [NPH] or lente) and short-acting (regular or Humalog) insulin twice a day, or regular insulin before meals and intermediate-acting insulin at bedtime. [source, 2005]
He was on insulin Humalog TID (42–46 U) with insulin NPH 90 U at bed time, for a total of > 200 U of insulin daily. [source, 2004]